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ABSTRACT
Trastuzumab is established as treatment of HER2high metastatic breast cancers 
but many limitations impair its efficacy. Here, we report the design of a Fab-like 
bispecific antibody (HER2bsFab) that displays a moderate affinity for HER2 and a 
unique, specific and high affinity for FcγRIII. In vitro characterization showed that 
ADCC was the major mechanism of action of HER2bsFab as no significant HER2-driven 
effect was observed. HER2bsFab mediated ADCC at picomolar concentration against 
HER2high, HER2low as well as trastuzumab-refractive cell lines. In vivo HER2bsFab 
potently inhibited HER2high tumor growth by recruitment of mouse FcγRIII and IV-
positive resident effector cells and more importantly, exhibited a net superiority over 
trastuzumab at inhibiting HER2low tumor growth. Moreover, FcγRIIIA-engagement 
by HER2bsFab was independent of V/F158 polymorphism and induced a stronger NK 
cells activation in response to target cell recognition. Thus, taking advantage of its 
epitope specificity and affinity for HER2 and FcγRIIIA, HER2bsFab exhibits potent 
anti-tumor activity against HER2low tumors while evading most of trastuzumab Fc-
linked limitations thereby potentially enlarging the number of patients eligible for 
breast cancer immunotherapy. 
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) 
is involved in complex signaling pathways controlling 
cell growth, survival and proliferation depending on the 
triggered signaling cascades [1]. Highly overexpressed 
in 20-25% of breast cancers, HER2 is associated with 
aggressive disease, increased metastasis potential and poor 
clinical outcome. The humanized monoclonal antibody 
trastuzumab (Herceptin®), first agent used for targeting 
HER2, is still standard of care as single agent [2] and 
in combination with chemotherapy in both early-stage 
and metastatic breast cancers strongly overexpressing 
HER2 [3, 4]. However, despite its irrefutable benefit, a 
significant subset of patients (~70%) with metastatic 
disease shows a resistance ab initio to trastuzumab as 
single agent and the majority of treated patients develop 
resistance within one year of treatment [5, 6]. Therefore, 
primary and acquired resistances to trastuzumab treatment 
represent an important clinical challenge. Moreover, up to 
now, the guidelines for trastuzumab treatment eligibility 
exclude patients with tumors displaying an HER2 
immunohistochemistry (IHC) score of 1+/2+.
Trastuzumab exerts its anti-tumor activity via 
the blockade of constitutive HER2 signaling and the 
recruitment of FcR expressing immune effector cells 
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responsible for antibody-dependent-cell cytotoxicity 
(ADCC) [7]. Although the exact contribution of each of 
these mechanisms in vivo is difficult to assess, pre-clinical 
studies provide evidence of the importance of ADCC in 
trastuzumab-based therapy [8-10]. The increased number 
of tumor-infiltrated NK cells observed in tumor tissue 
after trastuzumab treatment also supports the hypothesis 
of immune cells recruitment by the antibody [11, 12]. 
Importantly, FcγRIIIA-158 polymorphism has been shown 
to significantly influence the efficacy of trastuzumab in 
breast cancer patients [13]. Finally, Park et al [14] recently 
suggested a contribution of an adaptive immune response 
involving CD8+ T cells, dependent on the initial antibody-
triggered innate response through the production of 
cytokines and/or danger signals by FcR+ cells. However, 
besides FcγRIIIA-158 polymorphism, competition with 
endogenous IgGs and engagement of inhibitory antibody 
receptors (FcγRIIB) have been demonstrated to drastically 
hinder its capacity to mediate efficient ADCC.
Consequently, tremendous efforts are ongoing 
either to improve the clinical efficacy of trastuzumab or 
to develop new strategies [15-20]. A promising alternative 
is the design of bispecific antibodies (bsAb) able to 
efficiently recruit and activate effector cells at the tumor 
site. After a first craze in the 90s stopped by inconsistent 
clinical response and immunotoxicity, a revival of interest 
for bispecific antibodies has emerged from the evolution 
in antibody engineering. This led to the development of 
a large number and a wide variety of bispecific formats 
based on either IgG or non-IgG scaffolds [21, 22]. 
Although retargeting of various cytotoxic effector cells 
is exploited, many bispecific antibodies aim at activating 
T-cells based on their numeric superiority and their high 
intrinsic toxicity, some of them being currently under 
clinical investigations [23-25].
FcγRIIIA positive cells are however interesting 
to target. In addition to their intrinsic capability to 
attack tumors, NK cells are not affected by the various 
mechanisms put in place by tumor cells to escape their 
recognition by T cells. FcγRIIIA is also expressed on 
monocytes and macrophages [26] that are important 
actors of anti tumor immunity [27]. Moreover, in contrast 
to CD3 targeting, FcγRIIIA targeting does not induce the 
recruitment and activation of Treg cells, a subset of cells 
able to downregulate the antitumor immunity. However, 
despite very encouraging in vitro or pre-clinical results, 
limited clinical data are available on the efficacy of 
FcγRIII-targeting bispecific antibodies [28] and thus 
far, only one antibody, a bispecific TandAb targeting 
CD30 and FcγRIIIA [29] is ongoing a clinical study 
[NCT01221571].
In a previous study [30], we designed a bispecific 
antibody based on the natural affinity of human CH1 and 
Cκ IgG domains as a heterodimerization motif and the 
unique structural and functional properties of llama single 
domain antibodies. 
In this study, we have exploited the modular 
structure of the bsFab format to produce a Fab-like 
bispecific antibody (HER2bsFab) targeting binding sites 
on HER2 and FcγRIIIA different from those targeted 
by trastuzumab and conventional IgGs. A side by side 
comparison of HER2bsFab with trastuzumab has been 
conducted in vitro and in a mouse model to characterize 
its anti-tumor efficacy against high- and low-HER2-
overexpressing, as well as trastuzumab-refractive breast 
cancer tumors.
RESULTS
HER2bsFab binds simultaneously to HER2 and 
FcγRIIIA
 Based on the modular nature of the previously 
described compact and linker-free format [30], we 
designed a bsFab (HER2bsFab) targeting HER2-
expressing cancer cells and FcγRIII positive effector cells 
(Fig. 1A). HER2bsFab was expressed in the periplasm of 
E. coli and purified to homogeneity by a two-step affinity 
Table 1: Apparent affinities of HER2bsFab and trastuzumab for human Fcγ receptors. 
KD of trastuzumab
(nM)
KD of HER2bsFab
(nM)
Human
FcγRI 16.3 +/- 5.8 nd
FcγRIIA-131 H 235 +/- 7.1 nd
FcγRIIA-131 R 258.4 +/- 12.6 nd
FcγRIIB 66.7 +/- 4.2 nd
FcγRIIC nd nd
FcγRIIIA-158 F 194.3 +/- 1.5 10.3 +/- 0.6
FcγRIIIA-158 V 20.4 +/- 4.4 8.7 +/- 0.1
FcγRIIIB / NA1 330 +/- 15.2 12.3 +/- 0.2
FcγRIIIB / NA2 276.6 +/- 1.2 8.2 +/- 0.6
FcγRIIIB / SH 144.4 +/- 9.3 7.7 +/- 1
Values with error bars represent mean ± SEM. nd: no detectable binding. 
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chromatography procedure. HER2bsFab was produced at 
high yield (2-4 mg/L) and demonstrated a high stability 
as no significant decrease of binding was observed on 
SK-OV-3 or Jurkat-huFcγRIIIA cells after a three-week 
incubation at 37°C in non-heated human serum (Fig. S1). 
The binding activity of HER2bsFab was investigated 
by flow cytometry on HER2high breast cancer cells (SK-
BR-3 and BT 474) and human FcγRIIIA-transfected Jurkat 
cells (Fig. 1B-C). HER2bsFab efficiently bound all cell 
lines as more than 90% of cells were positively stained. 
Worth mentioning, no binding was detected on the non-
tumorigenic mammary epithelial cell line, hTERT-HME1, 
which expresses a basal level of HER2 (Fig. 1B, right 
panel). Relative to trastuzumab, HER2bsFab displayed a 
Figure 1: HER2bsFab simultaneously binds to cell surface HER2 and FcγRIIIA. A) Schematic representation of the 
assembled HER2bsFab. Dark grey, Cκ and CH1 constant domains of human IgG1; Light grey, anti-FcγRIII sdAb (clone CD16.21); White, 
anti-HER2 sdAb (clone HER2.C7b); C, 6H and F, c-myc, hexahistidine and Flag Tag respectively. Binding of biotinylated HER2bsFab 
and trastuzumab (100 nM) to B) HER2-positive (SK-BR-3, BT 474), HER2-negative (hTERT-HME-1) or C) FcγRIIIA expressing Jurkat-
huFcγRIIIA cells was analyzed by flow cytometry. PE-labeled streptavidin was used for detection. D) Rosette forming cells assay: CFSE 
labeled SK-OV-3 (white arrows) and Red CMTPX labeled Jurkat-huFcγRIIIA (black arrows) cells were co-cultured with irrelevant bsFab, 
HER2bsFab or trastuzumab (40 nM) and rosette formation was observed by optical and fluorescent microscopy. Representative images 
of different conditions are shown. E) Competition assay with endogenous IgG: Jurkat-huFcγRIIIa cells were incubated with biotinylated 
HER2bsFab (50 nM) or trastuzumab (200 nM) in presence of various concentrations of human serum. Bound antibodies were detected 
using PE-labeled streptavidin. 
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lower apparent affinity (80.1 +/- 13 nM vs. 6.8 +/- 0.6 nM) 
for HER2 partly explained by its monovalency. Binding 
of HER2bsFab was determined on all human FcγR 
using CHO cells expressing FLAG-tagged FcγR (Table 
1). Expression levels of FcγR were checked by labeling 
cells with anti-FLAG. Unlike trastuzumab which bound 
to all FcγR except FcγRIIC, HER2bsFab bound only 
to FcγRIIIA and B. Regarding FcγRIIIA, trastuzumab 
binding was variable according to the FcγRIIIA-158 
allotypes, with a 10-fold lower affinity for FcγRIIIA-158 
F/F while HER2bsFab exhibited similar and high apparent 
affinities for both FcγRIIIA-158 allotypes. The dual 
specific binding of HER2bsFab to HER2 and FcγRIIIA 
was demonstrated by its capacity to induce, in vitro, the 
formation of rosettes of Jurkat-huFcγRIIIA cells around 
HER2-positive SK-OV-3 cells (Fig. 1D). No rosette 
forming cells were observed when an irrelevant bsFab 
targeting FcγRIII but not HER2 was used. Furthermore, 
consistent with the targeting of an original FcγRIIIA 
epitope [31], we confirmed that, contrary to trastuzumab, 
HER2bsFab did not compete with endogenous serum IgG 
for binding to FcγRIIIA (Fig. 1E), strongly suggesting that 
HER2bsFab must escape competition with serum IgG in 
vivo. 
HER2bsFab does not inhibit cell growth
 Anti-proliferative effects of HER2bsFab were 
determined by following SK-BR-3 cell growth for 3, 5 
and 7 days in the presence of HER2bsFab or trastuzumab. 
No inhibitory effect of HER2bsFab was observed on SK-
BR-3 cell growth while a time-dependent inhibition was 
achieved in the presence of trastuzumab, the maximal 
growth inhibition reaching about 45% after 7 days (Fig. 
2A). In an attempt to explain why HER2bsFab had 
no anti-proliferative effect, we analyzed the impact of 
HER2bsFab on the activation of downstream MAPK and 
PI3K/AKT signaling pathways as these molecular events 
reflect HER2 activity (Fig. 2B). After an 8hr-incubation 
Figure 2: Anti-proliferative effects mediated by trastuzumab and HER2bsFab. A) SK-BR-3 cells growth was followed for 
3, 5 and 7 days in the presence of trastuzumab or HER2bsFab (500 nM). Cell viability was quantified using CellTiter Glo viability assay. 
Results are shown as percentage of control cell proliferation and expressed as mean ± SEM. All procedures were done in triplicate. B) 
Immunoblots evaluating the ability of HER2bsFab and trastuzumab (200 nM) to inhibit MAPK and Akt signalling pathways in SK-BR-3 
cells (incubation time: 8 h). Medium alone was used as a control. The experiments were performed three times. NT: non treated; Trast: 
trastuzumab; bsFab: HER2bsFab. Immunoblots were quantified using the NIH Image J software after correction for β-tubulin. Values are 
expressed as percentage of non treated cells signal. Values with error bars represent mean ± SEM. Data were analyzed by Student’s t-test. 
* P < 0.05 vs. non treated controls.
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with either 200 nM HER2bsFab or trastuzumab, SK-BR-3 
cell lysates were submitted to western blot analysis. While 
the levels of total MAPK and PI3K-Akt proteins were not 
modified, low but detectable changes in both pMAPK and 
pAkt levels were observed relative to untreated cells, upon 
HER2bsFab treatment (20-25%). As expected, a strong 
diminution of pMAPK and pAkt levels was observed 
in the presence of trastuzumab (60-70%). These results 
suggest that the slightly reduced activation of downstream 
intracellular pathways induced by HER2bsFab on SK-
BR-3 cells was no sufficient to induce an inhibition of cell 
growth.
HER2bsFab mediates potent NK cell cytotoxicity 
against HER2high breast cancer cells in vitro
The capacity of HER2bsFab to trigger tumor cell 
lysis by retargeting NK cells was investigated in vitro using 
a luminescent ATP-assay, as a nonradioactive alternative to 
Figure 3: HER2bsFab mediates potent in vitro ADCC activity similar to trastuzumab against high-HER2-overexpressing 
cells. A) ADCC assays were performed using human NK cells as effector cells and SK-BR-3, BT 474 or hTERT-HME-1 as target cells 
(E/T 10:1) in the presence of irrelevant bsFab, HER2bsFab or trastuzumab.Target cell viability was measured by CellTiter-Glo viability 
assay. Results are representative of at least three independent donors. Mean values ± SEM are presented. B) Impact of the E/T ratios on SK-
BR-3 and BT 474 cells lysis mediated by HER2bsFab or trastuzumab (100 nM). Data are representative of two experiments performed in 
triplicate, and represent the mean ± SEM. ns: non significant. C) Activation status of NK cells harvested from cytotoxicity assays illustrated 
in A) assessed for CD69 expression, detected with APC-conjugated anti-CD69. Secretions of D) granzyme B, E) IFNγ and F) TNFα were 
quantified by ELISA in supernatants from cytotoxicity assays against SK-BR-3 and BT 474 cells illustrated in A). Data are representative 
of at least two experiments performed in triplicate, and represent the mean ± SEM. Data were analyzed by Student’s t-test. * P < 0.05 vs. 
control; ** P < 0.01 vs. control; *** P < 0.001 vs. control; § P < 0.05 vs. trastuzumab; Ctrl: Control; Trast: trastuzumab.
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the conventional Cr51 assay. Figure 3 shows representative 
results using purified unstimulated human NK cells from a 
healthy donor as effector cells and HER2high breast cancer 
cells (SK-BR-3 and BT 474) or hTERT-HME1 as target 
cells (Fig. 3A). Very similar dose-dependent curves were 
obtained with trastuzumab and HER2bsFab at E/T ratio 
of 10:1 (Fig. 3A, left and middle panels) with comparable 
maximal levels of lysis (efficacy) of about 60-80% and 
similar EC50 values (potency) (2-6 pM). Since no growth 
inhibition was detected after overnight incubation of 
HER2high cancer cells with saturating concentrations 
of trastuzumab or HER2bsFab, cell lysis was directly 
correlated to ADCC. Importantly, no NK cytotoxic activity 
was observed when an irrelevant bsFab that elicited a 
cytolytic response in different experimental settings [30] 
or when hTERT-HME-1 cells were used (Fig. 3A, right 
panel). Lowering the E/T ratio down to 1:1 resulted in a 
significant but similar reduction of lysis to about 30% both 
for trastuzumab and HER2bsFab (Fig. 3B), indicating that 
HER2bsFab remained at least as efficient as trastuzumab 
at low E/T ratios. 
To assess that HER2bsFab-mediated lysis was 
correlated to FcγRIIIA engagement, the activation state 
of NK cells, harvested from ADCC assay against SK-
BR-3 cells (E/T 10:1), was evaluated by following 
the expression of the activation marker CD69 by flow 
cytometry (Fig. 3C). No significant up-regulation of 
CD69 was observed in the presence of the irrelevant 
bsFab confirming that NK cells activation was strictly 
dependent on the dual engagement of both receptors. 
The proportion of activated NK cells was slightly higher 
with HER2bsFab (77%) than with trastuzumab (61%), 
maybe due to its higher FcγRIIIA-affinity. Secretion 
of granzyme B, a key cytotoxic molecule released by 
activated NK cells, was also quantified in supernatants 
harvested from ADCC assays against SK-BR-3 and BT 
474 cells (Fig. 3D, left panel). Consistent with the results 
obtained with CD69, we found that HER2bsFab induced 
a granzyme B release moderately but significantly higher 
compared with trastuzumab. Finally, as effective antitumor 
immune responses are known to require the secretion of 
inflammatory cytokines such as IFNγ or TNFα, the ability 
of HER2bsFab to induce cytokines release in response to 
target cells was investigated (Fig. 3D, middle and right 
panels). Measurements of extra cellular INFγ and TNFα 
performed on ADCC supernatants showed that NK cells 
secreted higher amount of both cytokines in response to 
bsFab-coated SK-BR-3 and BT 474 cells compared with 
trastuzumab-coated cells. Taken together, these results 
demonstrated that, through dual engagement of HER2 
and FcγRIIIA, HER2bsFab is able to strongly activate NK 
cells, leading to a potent and highly specific cytotoxicity 
toward high-HER2-overexpressing tumor cells and the 
secretion of pro-inflammatory cytokines. 
HER2bsFab mediates potent in vitro ADCC 
against both trastuzumab refractive and low-
HER2-overexpressing breast cancer cells.
 We next determined whether enhanced affinity 
for FcγRIIIA could be translated into increased ADCC 
activity against trastuzumab-refractive and low-HER2-
overexpressing breast cancer cell lines. To support 
this hypothesis, we evaluated the cytotoxic activity of 
HER2bsFab against two different breast cancer cell lines, 
MCF-7 which weakly overexpresses HER2 and JIMT-1 
which, although overexpressing HER2, displayed a low 
trastuzumab-binding capacity due to overexpression of 
mucin 4 (MUC4) [32].
The mean number of accessible HER2 binding sites 
(specific antigen binding capacity, SABC) of the different 
cell lines was first estimated by the Dako QIFIKIT® (Fig. 
4A). According to the consensual clinical classification 
of HER2 expression in tumors, MCF-7 cells (HER2low / 
IHC score 1+) weakly overexpressed HER2 with a SABC 
(~7,260 sites/cell) significantly lower than SK-BR-3 or 
BT 474 cells (HER2high/ IHC score 3+, SABC > 400,000 
sites/cell) but still significantly higher than hTERT-HME1 
cells (SABC ~127 sites/cell). In accordance with the 
results described by Nagy et al. [33], and despite similar 
number of HER2 gene copies, the amount of accessible 
HER2 receptors at the surface of JIMT-1 cells (SABC 
~53,800) appeared to be about 8 to 10-fold lower than 
that determined for the two HER2high cancer cells, due to 
overexpression of MUC4. Consistent with these results, 
JIMT-1 and MCF-7 cells displayed a significantly weaker 
labeling with both trastuzumab and HER2bsFab compared 
to SK-BR-3 or BT 474 cells (Fig. 4B). Nevertheless, 
HER2bsFab binding activity still remained efficient on 
these two cell lines as more than 90% of cells were labeled 
in each case. 
Cytotoxic assays were then performed, using 
purified resting human NK cells and E/T ratio of 10:1 
(Fig. 4C). As expected, trastuzumab triggered low levels 
of ADCC against MCF-7 and JIMT-1 cells (40 and 38% 
respectively). By contrast, HER2bsFab demonstrated 
high cytotoxic activity on both cell lines, with maximum 
rates of specific lysis of 78% and 62% respectively. 
Interestingly, the higher ADCC potential of HER2bsFab 
against MCF-7 cells remained evident at the three E/T 
ratios tested (Fig. 4D, right panel). On the contrary, the 
difference in ADCC activity against JIMT-1 cells between 
the two antibodies faded at the lowest E/T ratio (Fig. 4D, 
left panel). 
We subsequently measured the release of granzyme 
B and pro-inflammatory cytokines in the supernatants 
harvested from above ADCC assays (Fig. 5). As could be 
expected from the decrease of trastuzumab efficiency, the 
amounts of granzyme B and pro-inflammatory cytokines 
released during trastuzumab-driven ADCC against both 
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MCF-7 and JIMT-1 cells were rather low, not always 
reaching significance over spontaneous release. Likewise, 
granzyme release and cytokine secretion by NK cells were 
also impaired in response to HER2bsFab-coated cells, 
albeit to a lesser extent. This finding, in line with those 
obtained with high-HER2-overexpressing cells, supported 
the idea that HER2bsFab is more potent than trastuzumab 
for inducing NK cell activation whatever the level of 
HER2 expression.
HER2bsFab mediates in vivo antitumor responses 
against both HER2high and trastuzumab-refractive 
tumors
Before investigating the therapeutic activity of 
the two antibodies in mouse models, their binding to 
Figure 4: In vitro, HER2bsFab induces potent ADCC against low-HER2-overexpressing and trastuzumab refractive 
cells. A) Specific HER2 binding capacities of SK-BR-3, BT 474, JIMT-1, MCF-7 and hTERT-HME-1 cells were assessed by DAKO 
QIFIKIT. Values with error bars represent mean ± SEM. Data were analyzed by Student’s t-test. *** P < 0.001 vs. HME-1 cells. B) Binding 
of isotype control, biotinylated trastuzumab or biotinylated HER2bsFab to JIMT-1 or MCF-7 cells. Bound antibodies were detected using 
PE-labeled streptavidin. C) ADCC assays were performed using JIMT-1 or MCF-7 cells as target cells and human NK cells as effector cells 
(E/T 10:1) and HER2bsFab or trastuzumab. Target cell viability was measured by CellTiter Glo viability assay. Results are representative 
of at least three independent donors. Values with error bars represent mean ± SEM. D) Impact of the E/T ratios on JIMT-1 or MCF-7 cells 
lysis mediated by HER2bsFab or trastuzumab (100 nM) cells. Values with error bars represent mean ± SEM and are representative of two 
experiments performed in triplicate. Data were analyzed by Student’s t-test. ** P < 0.01 vs. trastuzumab; *** P < 0.001 vs. trastuzumab.
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murine FcγR was checked by flow cytometry on stably 
transfected CHO cells expressing FLAG-tagged murine 
FcγR (Table 2). As expected, trastuzumab bound all four 
murine activating and inhibiting FcγR, with apparent 
affinities ranging from 46 to 309 nM, while HER2bsFab 
only recognized FcγRIII and FcγRIV (KD ~ 20 nM). These 
results were consistent with those on immune effector cells 
collected from spleen of nude mice demonstrating that 
both antibodies were able to bind on murine macrophages, 
monocytes, NK cells and neutrophils (Fig. S2). 
Knowing that HER2bsFab interacts with mouse 
resident immune cells, HER2bsFab in vivo activity was 
examined using HER2high (BT 474), HER2low (MCF-7) 
and trastuzumab-refractive (JIMT-1) xenograft models. 
BT 474 cells were chosen as SK-BR-3 cells have been 
reported to poorly form xenograft in athymic mice [34]. 
Athymic NMRI Nude mice were injected with 107 cells 
subcutaneously and treatments were started once tumors 
reached about 180-250 mm3. Irrelevant bsFab and 
HER2bsFab were injected i.p. at 5 mg/kg three times per 
week while trastuzumab was injected at the same dose two 
times per week. In all xenograft models, a 100% tumor-
take was reached and no adverse effects on body weight or 
general behavior were observed for all treated mice. 
As shown in Figure 6A, HER2bsFab displayed 
a potent anti-tumor activity comparable to that of 
trastuzumab against BT 474 cells, as evidenced by the 
statistically different size of tumors between controls (PBS 
and irrelevant bsFab) and treated groups. Importantly, 
no significant difference was observed between control 
Figure 5: HER2bsFab efficacy against trastuzumab-
refractive cells acts through an efficient activation of 
NK cells. NK activation was assessed by evaluating secretion 
of granzyme B, IFNγ and TNFα in supernatants of cytotoxicity 
assays on A) JIMT-1 and B) MCF-7 cells by ELISA. 
Measurements were performed in triplicate. Values with error 
bars represent mean ± SEM. Data were analyzed by Student’s 
t-test. * P < 0.05 vs. control; ** P < 0.01 vs. control; § P < 0.05 
vs. trastuzumab; §§ P < 0.01 vs. trastuzumab.
Figure 6: In vivo anti-tumor activity of HER2bsFab. 
All tumors were xenografted subcutaneously in NMRI Nude 
mice. Tumor volumes of A) BT 474 or B) MCF-7 tumors were 
measured after treatment with irrelevant bsFab (5 mg/kg), 
HER2bsFab (5 mg/kg), PBS (control buffer) or trastuzumab 
(5 mg/kg). Values with error bars represent mean ± SEM. 
Data were analyzed by One way ANOVA test. *** P < 0.001 
vs. control buffer group; ### P < 0.001 vs. irrelevant bsFab 
group; ## P < 0.01 vs. irrelevant bsFab group; §§§ P < 0.001 
vs. trastuzumab group. Beginnings of treatments were illustrated 
by black arrows. Representative images of tumors treated with 
negative controls, trastuzumab or HER2bsFab are illustrated for 
each model. 
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buffer and irrelevant bsFab suggesting that the antitumor 
response produced by HER2bsFab is specific to HER2 
recognition. Regarding the JIMT-1 xenograft model, 
trastuzumab moderately but significantly delayed JIMT-1 
tumor progression compared with the non-treated group 
(Fig. S3). HER2bsFab also tended to delay tumoral growth 
without, however, reaching a significant benefit over 
the control group. By contrast, HER2bsFab treatment 
significantly reduced MCF-7 tumor growth in comparison 
to PBS while no tumor growth delay was observed in 
tumor-bearing mice treated with trastuzumab (Fig. 6C). 
Altogether, these data demonstrated that, relative to 
trastuzumab, HER2bsFab displayed significant benefit for 
treating both in vitro and in vivo tumors overexpressing 
only weakly HER2.
FcγRIIIA-158 F/V polymorphism has no incidence 
on in vitro cytotoxic activity of HER2bsFab 
against HER2low tumor cells
As these promising pre-clinical results suggested 
potential clinical interest in extending the proportion of 
treatable HER2 breast cancers, one important issue to 
look at was the absence of influence of the FcγRIIIA-158 
F/V polymorphism in the case of tumors overexpressing 
only weakly HER2. Indeed, it has been shown that the 
FcγRIIIA-158 F/V and F/F allotypes, present in more 
than 80% of the caucasian population [13], are associated 
with worse clinical response upon trastuzumab treatment. 
In this respect, we showed that HER2bsFab-triggered 
ADCC against HER2low MCF-7 cells using NK cells from 
FcγRIIIA-158 V/V, F/F or V/F donors (E/T 5:1) was not 
affected by the FcγRIIIA-158 polymorphism as EC50 
values ranged from 44 to 56 pM and maximal lysis, from 
52 to 57% whatever the FcγRIIIA-158 allotype (Fig. 7). 
By contrast, as expected, both the potency and the efficacy 
of trastuzumab were significantly modulated according to 
FcγRIIIA-158 allotype. 
DISCUSSION
Trastuzumab represents the archetype of clinically 
effective targeted immunotherapy of solid tumors, as 
it has contributed to real improvements in the outcome 
of metastatic breast cancer strongly overexpressing 
HER2. However, significant subsets of patients do not 
benefit from trastuzumab treatment due either to primary 
Table 2:Apparent affinities of HER2bsFab and trastuzumab for mouse Fcγ receptors. 
KD of trastuzumab
(nM)
KD of HER2bsFab
(nM)
FcγRI 110.5 +/- 11.8 nd
FcγRIIB 309.1 +/- 27.9 nd
FcγRIII 198.2 +/- 4.5 17.2 +/- 0.58
FcγRIV 46.3 +/- 1.2 26.4 +/- 2
Values with error bars represent mean ± SEM. nd: no detectable binding. 
Figure 7: Effect of FcγRIIIA polymorphism on the ADCC triggered by HER2bsFab. ADCC assays were performed using 
human FcγRIIIA-158 V/V, F/V or F/F NK cells as effector cells and MCF-7 as target cells (E/T 5:1) in the presence of various concentrations 
of trastuzumab or HER2bsFab. All experiments were performed two times in triplicate. Values with error bars represent mean ± SEM.
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resistance, to relapse during the course of treatment due 
to acquired resistance or to low HER2 IHC score [5, 6]. 
Besides the limitations related to its own characteristics, 
trastuzumab also suffers from the disadvantages of IgG 
antibodies, namely FcγRIIIA-158 polymorphism of NK 
cells [13], competition with endogenous IgG [35], binding 
on inhibitory receptor FcγRIIB [36] and Fc fucosylation 
issues [37]. Thus, considerable efforts are currently made 
to optimize the effector function of trastuzumab mainly 
through removal of fucose glycosylation [15] or through 
mutations to overcome the polymorphism issues [16, 
38]. However, although improving FcγRIIIA binding in 
a significant way, these strategies do not fully bypass the 
limitation of inhibitory FcγRIIB binding [16].
Another promising strategy is the development of 
bispecific antibodies able to recruit and activate various 
immune effector cells at the tumor site. Several anti-HER2 
bispecific antibodies targeting neutrophils, monocytes, 
and macrophages via FcγRI [39], T-cells via CD3/CD28 
[40-42] or NK cells via FcγRIIIA [43, 44] have been 
designed. However, despite encouraging in vitro and 
preclinical results, only one bispecific antibody targeting 
CD3 [42] is under clinical trial, highlighting the need to 
improve further the design of these molecules. Using our 
versatile Fab-like bispecific antibody format [30] based on 
the use of llama single domain antibodies, we developed 
a bispecific antibody, named HER2bsFab, that targets 
human HER2 antigen and activating FcγRIIIA receptor. 
Consistent with our previous studies [30], 
HER2bsFab was well produced in E. coli and highly stable 
due to the absence of linker. Compared to optimized Fc 
formats, HER2bsFab displays unique and interesting 
features. It is selective for FcγRIII as no binding to 
FcγRI, FcγRIIA or inhibitory receptor FcγRIIB was 
observed. Moreover, it binds the FcγRIIIA receptor with 
an apparent affinity 36-fold higher than trastuzumab, 
targeting an epitope outside the Fcγ binding site [31], thus 
bypassing competition with endogenous IgG. HER2bsFab 
specifically binds to an epitope of the extracellular domain 
of HER2 that is different from that of trastuzumab [45], 
with an intermediate affinity (60 nM). This feature might 
be an advantage over trastuzumab as several studies 
have described the existence of a binding site barrier that 
limits tumor penetration of high affinity antibodies [46, 
47]. As well, Cao et al. [48] recently reported that high 
affinity scFv antibody-based immunotoxins induced more 
hepatotoxicity than their low affinity counterparts, due to 
an important formation of immune complexes with soluble 
shed tumor antigen. An intermediate affinity for the well 
known shed extracellular domain of HER2 could avoid 
such side effects. 
Exploration of in vitro direct HER2-driven 
properties of HER2bsFab showed that, unlike 
trastuzumab, HER2bsFab had no anti-proliferative 
activity on HER2high SK-BR-3 cell, despite a minor 
effect on downstream MAPK and PI3K/Akt signaling 
pathways. This result could be explained by either the 
epitope specificity of HER2bsFab, its monovalency and/
or its intermediate affinity for HER2 as we demonstrated 
that the same anti-HER2 sdAb produced in a bivalent 
format (Fc fusion, apparent KD of 2 nM), showed an 
anti-proliferative effect (30%) at high concentration. As 
ADCC and signaling effects occur independently [49], 
the absence of anti-proliferative effects of HER2bsFab 
should not be detrimental for in vivo anti-tumor activity 
and could avoid the development of resistance related to 
upregulation of alternative signaling pathways and/or to 
altered intracellular signaling observed upon long-term 
exposure to trastuzumab [50, 51]. 
We showed that HER2bsFab-mediated ADCC 
against HER2high breast cancer cells was similar to that 
of trastuzumab both in terms of efficacy (maximal lysis) 
and potency (EC50), even at low E/T ratio (1:1). Worth 
mentioning, HER2bsFab retained its high ADCC activity 
at picomolar concentration using unstimulated human 
PBMC as effectors (E/T: 25/1, Fig. S4). The presence of 
neutrophils in vitro did not appear to modify the killing 
efficacy of HER2bsFab, in agreement with previously 
published data [52] (Fig. S5). The analysis of ADCC 
pathway showed that, through FcγRIIIA engagement, 
HER2bsFab, as trastuzumab, induces a perforin-mediated 
cytotoxicity, stimulating NK cell degranulation and 
cytokine secretion in response to target cell recognition. 
Fauriat et al [53] have shown that different thresholds exist 
in activating signals to induce NK cell effector responses: 
chemokine secretion requires the lowest activating signals, 
moderate ones induce degranulation and the strongest 
ones induce cytokine secretion. Interestingly, relative 
to trastuzumab, HER2bsFab elicited a higher level of 
secreted IFNγ suggesting that HER2bsFab induces a 
stronger NK activation signal. This finding was consistent 
with the slightly greater percentage of CD69 positive NK 
cells and the much higher level of granzyme B, further 
emphasizing the substantial difference in FcγRIIIA 
engagement between HER2bsFab and trastuzumab, 
likely due to more stable crosslinking of FcγRIIIA by 
HER2bsFab. However, despite the higher NK activation 
mediated by HER2bsFab, no difference in maximum lysis 
was observed compared with trastuzumab against both 
SK-BR-3 and BT 474 cells. One explanation could be that 
the high HER2 density displayed by these cell lines shades 
off the differences in affinity for both HER2 and FcγRIIIA 
between the two antibodies, the bivalence of trastuzumab 
against HER2 compensating its low affinity for FcγRIIIA. 
The more potent effector functions mediated by 
HER2bsFab raise the hypothesis that HER2bsFab could 
potentially be beneficial in a context of trastuzumab-
refractive and low-HER2-overexpressing breast cancers. 
To address this question, we analyzed the in vitro efficacy 
of HER2bsFab against two models of trastuzumab 
refractive breast cancers: MCF-7, an HER2 non-amplified 
cell line not eligible to trastuzumab treatment due to 
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a weak HER2 overexpression, and JIMT-1, a model 
of HER2-overexpressing, trastuzumab resistant cell 
line. Several mechanisms are likely underlying JIMT-1 
resistance among which (i) a partial masking of HER2 by 
overexpressed MUC4 [33] and (ii) the absence of HER2-
driven effects of trastuzumab [54]. The absence of anti-
proliferative effects of either trastuzumab or HER2bsFab 
on these two cell lines allowed a direct comparison of their 
ADCC capacity.
For sake of comparison between cell lines and 
because heterogeneous data are found in the literature 
regarding the HER2 status of MCF-7, maybe due to 
biological differences among MCF-7 cell lines [55], 
the HER2 binding capacity of all cell lines tested was 
assessed. We thus confirmed that MCF-7 cells displayed 
a low but significant HER2 overexpression (SABC 60-
fold higher than that of hTERT-HME-1 cells) despite 
an absence of gene amplification. We show in this study 
that in vitro, HER2bsFab retained its full killing efficacy 
against both JIMT-1 and MCF-7 cells at high E/T ratio 
(10/1) independently of HER2 status while trastuzumab-
mediated ADCC proved to be much less efficient than 
against HER2high cells. NK cell activation mediated by 
HER2bsFab upon trastuzumab-refractive cell engagement 
still remained stronger than that mediated by trastuzumab 
as demonstrated by higher secretion levels of granzyme 
B and pro-inflammatory cytokines. Taken together, these 
results suggest that comparatively to trastuzumab, the 
threshold of HER2 density on target cells required for 
inducing HER2bsFab-mediated NK cell activation and 
ADCC was lower, maybe due to its enhanced FcγRIIIA 
binding.
 Interestingly, at low E/T ratio (1:1), a condition 
closer to the situation at the tumor site, HER2bsFab still 
remained significantly more potent than trastuzumab for 
inducing MCF-7 lysis, underlying the potential benefit of 
HER2bsFab against tumors expressing low HER2 levels 
in vivo. 
Taking benefit from the fact that HER2bsFab can 
bind mouse resident immune cells including NK cells, 
macrophages and neutrophils, we demonstrated that 
HER2bsFab triggers a potent ADCC activity in vivo. 
In NMRI Nude mice with established HER2high BT 474 
xenograft, HER2bsFab displayed the same potential as 
trastuzumab at inhibiting tumor growth. In the absence 
of anti-proliferative properties, the HER2bsFab-mediated 
effects on tumor growth can exclusively be attributed 
to ADCC and these effects are target-restricted since an 
irrelevant bsFab had no impact on tumor growth. Although 
the toxicity of the HER2bsFab remains to be further 
evaluated, it must be pointed out that, in all in vivo studies, 
no apparent detrimental off target toxicity was observed as 
monitored by animal survival and weight curves despite 
repeated injections. Along this line, we showed that, in 
vitro, HER2bsFab was unable to elicit ADCC against 
the non-tumorigenic human mammary epithelial cells 
(hTERT-HME1). 
In a context of low-HER2-overexpressing and 
trastuzumab-refractive tumors, the potency of bsFab 
was tested in NMRI Nude mice with established MCF-
7 or JIMT-1 xenografts. Consistent with several studies 
showing the ability of trastuzumab to inhibit outgrowth 
of detectable JIMT-1 tumors [54, 56], a moderate growth 
inhibition was observed with trastuzumab. Unexpectedly, 
while a stronger inhibitory effect of bsFab could have been 
expected based on in vitro ADCC assays, HER2bsFab 
reduced JIMT-1 tumor growth, closely approaching 
significance (P=0.057). This finding could be related to the 
observation that the difference in ADCC activity between 
the two antibodies was abrogated, in vitro, at low E/T 
ratio (1:1) with this cell line. In contrast, a more striking 
difference was observed on established MCF-7 xenografts. 
Unlike trastuzumab that, as described in the literature, had 
no effect against MCF-7 tumors, HER2bsFab induced a 
significant slowdown of tumor growth suggesting that 
HER2bsFab could provide a clinical benefit in the case of 
both high- and low-HER2-overexpressing breast cancers. 
Our results are in line with recent reports on the 
benefit of enhancing trastuzumab affinity for FcγRIIIA 
on its antitumor activity in vivo [15, 16] and emphasize 
the role of ADCC as mechanism of action in the in vivo 
antitumor effects of ADCC-promoting antibodies in solid 
tumors. Moreover, by targeting an epitope on FcγRIIIA 
distant from the Fc binding site, HER2bsFab completely 
bypasses the FcγRIIIA-158 polymorphism issue that 
restricts the therapeutic efficiency of trastuzumab [13] 
for all FcγRIIIA-158 F carriers. HER2bsFab could 
thus represent an interesting approach for an efficient 
HER2-targeting treatment independent of both patient 
FcγRIIIA-158 phenotype and HER2 status. Recently, 
clinical evidences have been reported on the benefit of 
multiple HER2-targeted therapies [57, 58]. In this regard, 
the different epitope specificities of HER2bsFab for 
both HER2 and FcγRIIIA compared with trastuzumab 
and pertuzumab [31, 45] could be of clinical interest for 
combinatorial therapies, as no interference in binding and 
killing efficacy should be expected. Finally, in addition to 
patients with low HER2 IHC score, patients experiencing 
tumor progression during trastuzumab-based treatment 
may also benefit from HER2bsFab. 
In conclusion, we have designed a bispecific 
antibody displaying a moderate affinity for the tumor-
targeted antigen and a unique, specific and high FcγRIII-
binding affinity using ADCC as major mechanism of 
action. Endowed with a high potential to inhibit HER2high 
tumor growth, HER2bsFab also overcomes in vitro 
and in vivo limitations associated with the threshold of 
HER2 expression level on target cells and with NK cell 
polymorphism for eliciting efficient anti-tumor activity. 
This study raises the perspective to enable the treatment 
of a broader population of patients than that eligible with 
current HER2-targeted therapies.
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MATERIALS AND METHODS
Construction and production of HER2bsFab
The anti-HER2 x FcγRIII bispecific antibody was 
constructed by cloning cDNA of the anti-HER2 sdAb 
(HER2.C7b) [59] into the expression vector pBAT14 
upstream the anti-FcγRIII sdAb (CD16.21) cDNA [30]. 
The resulting bispecific antibody, named HER2bsFab, was 
produced in E.coli (DH5α strain) periplasm and purified as 
previously described [30]. Endotoxin concentration was 
checked using the Pierce LAL Chromogenic Endotoxin 
Quantitation Kit (Thermo Scientific). Commercial 
trastuzumab (Herceptin®, Roche) was a kind gift from 
TrGET platform (U1068 INSERM, Marseille, France). 
Effector cells and target cell lines
Breast cancer cell lines SK-OV-3 (ATCC HTB-77), 
SK-BR-3 (ATCC HTB-30), BT-474 (ATCC HTB-20), 
MCF-7 (ATCC HTB-22) and the immortalized epithelial 
cell line hTERT-HME-1 (ATCC CRL-401) were purchased 
from ATCC and JIMT-1 (ACC 589) cell line from DSMZ. 
Human FcγRIIIA transfected Jurkat lymphoma T cells 
(Jurkat-huFcγRIIIA cells) were a gift of Pr. Eric Vivier 
(Marseille, France) and were not authenticated. Stably 
transfected CHO cells expressing FLAG-tagged human 
FcγRI (CNCM I-4383), FcγRIIA-131 H (CNCM I-4384), 
FcγRIIA-131 R (CNCM I-4385), FcγRIIB (CNCM 
I-4386), FcγRIIC (CNCM I-4387), FcγRIIIA-158 F/F 
(CNCM I-4388), FcγRIIIA-158 V/V (CNCM I-4389), 
FcγRIIIB/NA1 (CNCM I-4390), FcγRIIIB/NA2 (CNCM 
I-4391), FcγRIIIB/SH (CNCM I-4392) were provided by 
Collection Nationale de Cultures de Microorganismes 
(CNCM, Institut Pasteur, France) [60]. Stably transfected 
CHO cells expressing FLAG-tagged mouse FcγRs 
were reported before [61]. Human peripheral blood 
mononuclear cells (PBMCs) were isolated from fresh 
peripheral blood of healthy donors (Etablissement 
Français du Sang (EFS), Marseille, France) by Ficoll LSM 
1077 (PAA) gradient centrifugation. All donors were of 
FcγRIIIA-158 F/F or F/V phenotype unless otherwise 
stated. NK cells were isolated as previously described 
[30]. Frozen PBMCs from FcγRIIIA-158 V/V, F/F or V/F 
donors were kindly provided by Dr. Christophe Picard 
(EFS, Marseille, France). 
Characterization of HER2bsFab by fluorescence 
cytometry
HER2 binding capacity of tumor cell lines was 
quantified by DAKO QIFIKIT (DAKO Cytomation), 
according to the manufacturer’s protocol using mAb 
ER-23 (Santa Cruz) as primary antibody. HER2 quantity 
was expressed as specific antibody-binding capacity 
units after subtraction of isotype control (mouse IgG2b) 
background. For binding experiments, HER2bsFab and 
trastuzumab were biotinylated in vitro using Ez-link micro 
NMHS-PEO4-biotinylation kit (Perbio science). The 
impact of biotinylation on antigen binding was checked 
by comparing binding activities of biotinylated antibodies 
and their unlabeled counterparts by flow cytometry. 
Binding and apparent affinities were determined by flow 
cytometry as previously described [59] using 2x105 Jurkat-
huFcγRIIIA, SK-BR-3, stably transfected CHO cells 
expressing FLAG-tagged human or mouse FcγRs and 
biotinylated antibodies (0.05 nM to 2000 nM). Stability 
assays in human serum were performed as previously 
described [30] for 21 days with biotinylated antibodies. 
Competition assays with endogenous IgGs were 
performed by incubating Jurkat-huFcγRIIIA cells in the 
presence of human serum (20 or 100%) and sub-saturating 
concentration of biotinylated HER2bsFab (50 nM) or 
trastuzumab (200 nM). Bound antibodies were detected 
by flow cytometry using PE-labeled streptavidin [30].
Rosette forming cell assay
Rosette forming cell assays were performed as 
previously described [30]. SK-OV-3 cells (5x106) were 
labeled for 10 min at 37°C with 20 µM CellTrace™ 
CFSE (Invitrogen) in PBS/0.1% BSA and Jurkat-
huFcγRIIIA cells (5x106) for 30 min at 37°C with 100 µM 
CellTracker™ Red CMTPX (Invitrogen). 
In vitro viability assays
Target cells (5x103 cells) were seeded on 96-well 
plates, incubated overnight for cell attachment and treated 
or not with increasing concentrations (0.05 to 500 nM) of 
trastuzumab or HER2bsFab. After 3, 5 and 7 days, cell 
viability was quantified with CellTiter-Glo Luminescent 
Cell Viability Assay according to manufacturer’s 
protocol (Promega). Percent viability was calculated as 
follows: (TAb x 100) / T with T = Non-treated target cells 
luminescent signal, and TAb = Target cells + Antibody 
luminescent signal. All procedures were done in triplicate.
MAPK and Akt activation
After an 8hr-incubation in the absence or presence 
of 200 nM trastuzumab or HER2bsFab, SK-BR-3 cell 
lysates (25 µg) were separated by SDS-PAGE under 
reducing conditions. Western blots were probed with anti-
Akt (11E7, 1/1000), anti-pAkt (D9E, 1/2000), anti-MAPK 
(137F5, 1/1000) and anti-pMAPK (20G11, 1/1000) 
antibodies (Cell Signaling Technology) and anti-rabbit (sc-
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2004, 1/5000, Santa Cruz Biotechnology) or anti-mouse 
(A2304, 1/5000, Sigma-Aldrich) horseradish peroxidase 
(HRP)-conjugate secondary antibodies (sc-2004, Santa 
Cruz Biotechnology) for detection. β-tubulin detected with 
anti-tubulin (TUB 2.1, 1/4000, Sigma Aldrich) was used as 
protein loading control.
In vitro ADCC assays
Assays were performed as previously described 
[30]. Target cell viability was quantified using CellTiter-
Glo Luminescent Cell Viability Assay. Percent cytotoxicity 
was calculated as follows: [T - (TEAb - E)] / [(T - (Tdead - E)] 
× 100 with T = Target luminescent signal, E = effector 
luminescent signal, Tdead = luminescent signal of target 
cells lysed with 1% Triton X100 solution and TEAb = Target 
+ Effector + Antibody luminescent signal. 
NK activation assays
Supernatants were harvested from ADCC assays and 
frozen at -20°C. Secreted human IFNγ and TNFα were 
measured by ELISA using the READY-SET-GO human 
IFNγ or TNFα kits as described by the manufacturer 
(eBioscience). Secreted human granzyme B was measured 
by ELISA using the Human Granzyme B Platinum ELISA 
kit (eBioscience). Cell surface expression of CD69 on 
harvested NK cells was analyzed by flow cytometry 
after labeling with an APC-conjugated anti-CD69 IgG 
(Miltenyi).
Tumor growth studies
NMRI Nude mice were subcutaneously injected 
with 107 cells in a 1/2 (v/v) Matrigel/PBS suspension (BD 
Biosciences). When tumors reached an average of 180-250 
mm3, mice were randomly divided into treatment groups 
(n=6). HER2bsFab (5 mg/kg) and negative controls 
(saline buffer or irrelevant bsFab targeted to mesothelin 
(5 mg/kg)) were given intraperitoneally (i.p.) three times 
per week and trastuzumab (5 mg/kg) i.p. twice weekly. 
All experiments were performed in agreement with the 
French Animal Protection Law with the permission of 
local authorities
Statistical analysis
All data are presented as mean ± SEM. Statistical 
analysis of in vitro data was performed by Student’s 
unpaired t. In vivo data were analyzed by One-Way 
ANOVA test. Values of P < 0.05 were considered 
significant. 
Material and Methods are further detailed in the 
supplementary material.
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